Alan List - Jan 20, 2024 Form 4 Insider Report for PRECISION BIOSCIENCES INC (DTIL)

Role
Chief Medical Officer
Signature
/s/ Dario Scimeca, Attorney-in-Fact for Alan List
Stock symbol
DTIL
Transactions as of
Jan 20, 2024
Transactions value $
-$7,749
Form type
4
Date filed
1/23/2024, 07:13 PM
Previous filing
Apr 28, 2023
Next filing
Apr 30, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DTIL Common Stock Options Exercise +60K +106.22% 117K Jan 20, 2024 Direct F1, F2
transaction DTIL Common Stock Sale -$7.75K -21.5K -18.48% $0.36 95K Jan 22, 2024 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DTIL Restricted Stock Units Options Exercise $0 -60K -33.34% $0.00 120K Jan 20, 2024 Common Stock 60K Direct F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Represents the partial vesting and settlement of Restricted Stock Units ("RSUs") on January 20, 2024.
F2 Each RSU represents a contingent right to receive one share of the Issuer's Common Stock or, at the Issuer's option, an amount of cash equal to the fair market value of such share.
F3 The sales were effected pursuant to a Rule 10b5-1 plan adopted on September 10, 2021. The transaction was a sell-to-cover, with shares only sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The Reporting Person did not sell or otherwise dispose of shares reported on this Form 4 for any reason other than to cover required taxes and fees.
F4 On January 20, 2023 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2024, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.